IPN10200 dose A

Phase 2

Ipsen

IPN10200 dose A is one of 4 therapeutic programs targeting Episodic Migraine. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Episodic MigraineRecruiting

Episodic MigrainePhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Episodic Migraine

#DrugCompanyPhaseTrials

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 3

1 2

Qulipta

AbbVie

Phase 3

1 3

IPN10200

Ipsen

Phase 2

1 4

IPN10200 dose A

Ipsen

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Episodic Migraine

NCT06625060

Clinical

Trials by Indication[1]

Episodic Migraine1 trial

A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults

Recruiting· Ipsen logo

Ipsen·Phase 2·NCT06625060·641 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IPN10200 dose A. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for IPN10200 dose A. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Ipsen

IPN10200 dose A

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Episodic Migraine1 trial

References

Drug Info

Quick Facts

Related News